BindingDB logo
myBDB logout

39 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28131713 75 Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.EBI Merck Research Laboratories
26965854 96 Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach.EBI AstraZeneca
25801931 24 Pseudosaccharin amines as potent and selective KV1.5 blockers.EBI Bristol-Myers Squibb Research and Development
24881566 140 Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI GlaxoSmithKline
25155913 32 Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.EBI AstraZeneca
24881565 15 Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.EBI Bristol-Myers Squibb Research and Development
24824064 48 Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).EBI China Pharmaceutical University
23414837 35 Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.EBI Bristol-Myers Squibb
23121096 86 Ion channels as therapeutic targets: a drug discovery perspective.EBI Pfizer Inc.
23260347 58 Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5.EBI AstraZeneca
22770500 219 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models.EBI AstraZeneca
24900546 29 Symmetric kv1.5 blockers discovered by focused screening.EBI TBA
22409629 15 Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor.EBI Bristol-Myers Squibb
18374568 14 Pyrano-[2,3b]-pyridines as potassium channel antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17506538 27 Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.EBI Cardiome Pharma Corporation
11356099 20 Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.EBI Abbott Laboratories
21634377 73 Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.EBI Amgen Inc.
20974533 99 Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2.EBI GlaxoSmithKline Research and Development
20304642 41 Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.EBI Merck Research Laboratories
20097068 26 Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.EBI Bristol-Myers Squibb Pharmaceutical Research and Development
19665893 29 Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.EBI Bristol-Myers Squibb
19888755 43 Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.EBI Wyeth Research
19398199 24 Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.EBI Icagen Inc
19004630 35 Dihydropyrazolopyrimidine inhibitors of K(V)1.5 (I(Kur)).EBI Bristol-Myers Squibb
17462888 38 Benzopyran sulfonamides as KV1.5 potassium channel blockers.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17350840 9 Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.EBI Icagen Inc.
17125248 24 Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.EBI Merck Research Laboratories
17095219 20 Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.EBI Procter and Gamble Pharmaceuticals
17010606 6 Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers.EBI Procter & Gamble Pharmaceuticals
16949818 41 Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.EBI Merck Research Laboratories
16942878 8 Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers.EBI Procter and Gamble Pharmaceuticals
16942874 10 Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.EBI Procter & Gamble Pharmaceuticals
16793267 2 Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.EBI Procter & Gamble Pharmaceuticals
16480279 71 A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.EBI Institute of Medical Research Biotechnology Centre
15125940 30 Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.EBI Aventis Pharma Deutschland GmbH
12570371 33 Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.EBI Aventis Pharma Deutschland GmbH
9804693 20 Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.EBI University of Kiel
28418664 32 Selective IEBI Bristol-Myers Squibb